US PRE-MARKET MOVERS: AZN, CIBR, U, AGX, TRIP

ES -0.4% NQ -0.6% RTY -0.6%

• AZN +3.6%: Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials
• CIBR -2.4%: Reports emerge of leaked Anthropic AI model, "Claude Mythos"; co. believes it poses unprecedented cybersecurity risks
• U +14.1%: Raised Q1 revenue view; PT raised at BofA
• AGX +9.5%: Earnings beat; upgraded at JPM to 'Overweight' from 'Neutral'
• TRIP +3.8%: Upgraded at BofA to 'Buy' from 'Neutral'